Publikationen in Zusammenarbeit mit Forschern von University Hospital of Lausanne (19)

2024

  1. Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT)

    Lung Cancer, Vol. 187

  2. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases

    Lung Cancer, Vol. 188

2023

  1. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation

    ESMO Open, Vol. 8, Núm. 4

  2. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

    Journal of Thoracic Oncology, Vol. 18, Núm. 1, pp. 79-92

  3. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10378, pp. 733-746

  4. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

    Journal of Thoracic Oncology, Vol. 18, Núm. 8, pp. 1055-1069

2022

  1. Addressing CPI resistance in NSCLC: Targeting TAM receptors to modulate the tumor microenvironment and future prospects

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 7

  2. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

    Annals of Oncology, Vol. 33, Núm. 5, pp. 466-487

  3. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

    The Lancet Oncology, Vol. 23, Núm. 10, pp. 1274-1286

2019

  1. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2109-2119

2017

  1. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer

    New England Journal of Medicine, Vol. 376, Núm. 25, pp. 2415-2426

  2. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)

    Journal of Clinical Oncology

2016

  1. Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy

    ESMO Open, Vol. 1, Núm. 6

2015

  1. 2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer

    Annals of Oncology, Vol. 26, Núm. 8, pp. 1573-1588

2014

  1. 2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease

    Annals of Oncology, Vol. 25, Núm. 8, pp. 1475-1484

  2. 2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 25, Núm. 8, pp. 1462-1474

  3. Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer

    Annals of Oncology, Vol. 25, Núm. 9, pp. 1681-1690

2013

  1. Strategies for improving outcomes in NSCLC: A look to the future

    Lung Cancer, Vol. 82, Núm. 3, pp. 375-382

2012

  1. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure

    Clinical Cancer Research, Vol. 18, Núm. 11, pp. 3170-3179